faecalis strain ATCC 29212 were used as quality controls. For interpretation, we used epidemiologic cutoff values recommended by the European Committee on Antimicrobial Susceptibility Testing (http://mic.eucast.org). Multidrug non-wild-type phenotype was defined as non-wild-type MICs to ≥1 antimicrobial agents from ≥3 antimicrobial classes.
Production of extended-spectrum or AmpC β-lactamases was evaluated by a combined disc test that used discs of cefotaxime and ceftazidime with (30/10 μg) and without clavulanic acid (30 μg) and a disc of cefoxitin (30 μg) for all isolates; this process satisfied the phenotypic criteria indicative of extended-spectrum cephalosporinase production, as recommended by the European Centre for Disease Prevention Control (2).
Characterization of Resistance Determinants
We assessed the presence of genes conferring the extended-spectrum cephalosporinase-resistant phenotype. DNA was extracted by using the DNeasy Blood and Tissue kit (QIAGEN, Hilden, Germany) according to the manufacturer's recommendations.
All isolates putatively producing extended-spectrum or AmpC β-lactamases were screened for a broad spectrum of extended-spectrum and AmpC β-lactamase gene families by using the Check-MDR CT-101 array platform (Check-Points, Wageningen, the Netherlands) according to the manufacturer's recommendations. The presence of extended-spectrum or AmpC β-lactamase genes was confirmed by PCR and subsequent sequencing as described (3) . The nucleotide and deduced amino acid sequences were compared with sequences in the Lahey clinic database (http://www.lahey.org/Studies).
Clonal Analysis
All isolates carrying extended-spectrum or AmpC β-lactamases (n = 47) and isolates randomly selected on the basis of year and source of isolation (n = 64) were analyzed for genetic relatedness by pulsed-field gel electrophoresis (PFGE) of XbaI-digested genomic DNA by using a CHEF DR-III apparatus (Bio-Rad Laboratories, Hercules, CA, USA), according to the standardized protocol of PulseNet (4). XbaI-digested genomic DNA from S. enterica ser. Braenderup strain H9812 was used as a molecular reference marker (5). Image normalization and construction of similarity matrices were carried out by using BioNumerics, 
Plasmid Analysis
The replicon types were characterized for all plasmids carrying extended-spectrum or sequence typing (pMLST or pDLST) were used to further subtype IncI1 and IncHI2 plasmids as previously described (7, 8) . A subset of transformants (n = 16) was selected according to PFGE profile of the parental strain, replicon type of the plasmid, and antimicrobial-resistance determinant. These plasmids were subjected to S1-PFGE for accurate determination of molecular sizes (9) . If no transformants were obtained, the chromosomal location of the extended-spectrum or AmpC β-lactamase agar plates genes was confirmed by I-CeuI PFGE of total bacterial DNA, followed by Southern blot hybridization, as described (10) .
Conjugation Experiments
The transferability of the extended-spectrum cephalosporinase-resistant phenotype by conjugation was assessed for the subset of S. enterica ser. Heidelberg isolates described above. Plasmid-free rifampin-resistant E. coli E3110 was used as a recipient strain for liquidmating assays in a ratio of 1:1. Filter-mating assays were attempted for strains for which no transconjugants were obtained by liquid mating. For both liquid-and filter-mating assays, the donor and recipient strains in mid-exponential phase were co-incubated for 4 hours without 
Analysis of Regions Upstream of Resistance Determinants
The association of blaCTX-M and blaCMY genes with frequently encountered insertion sequences (ISEcp1, ISCR1, and IS26) was assessed for a subset of S. enterica ser.
Heidelberg isolates (n = 17) representing each unique PFGE profile and the variation in extended-spectrum or AmpC β-lactamase gene type and its location (chromosome or plasmid replicon type). This association was investigated with PCR by using forward primers specific for ISEcp1, ISCR1, or IS26 and a reverse primer for blaCTX-M or blaCMY genes, as described (11) . Subsequently, sequence analysis confirmed the amplicons obtained.
